Legendary Streetwear Designer Jeff Staple Teams up With the Overwatch League™ to Create First-of-its-kind Esports Kit
The Overwatch League™ today announced a first-of-its-kind collaboration with designer and streetwear powerhouse, Jeff Staple, to reimagine, design, and create an authentic player kit for esports. The new kits, designed in concert with Overwatch League player feedback for a look and feel that’s unique to both traditional sports and esports, feature elevated fabrics, premium graphic applications, new side gussets for adjustable comfort, and a fit that is cut and sewn to increase quality and wearability while gaming. Each of the 20 Overwatch League teams will have their own unique home and away kits during the 2020 season, which launches on Feb. 8.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200116005551/en/
(Photo: Business Wire)
Staple worked with Overwatch League players throughout the design process to ensure the kits are a comfortable, functional uniform for competition, while also maintaining Staple’s signature aesthetic. The new kits utilize elevated pin-dot mesh fabric to create lightweight and breathable jerseys to balance and regulate players’ temperature for maximum comfort. The full kit will include a short-sleeve jersey, long-sleeve jersey, jacket, compression sleeve, hat, and beanie for each of the league’s 20 teams.
“This first-of-its-kind collaboration is a great reflection of esports’ evolution into a true lifestyle. This is not just a win for the Overwatch League and our fans, but for esports as an industry,” Daniel Cherry, chief marketing officer at Activision Blizzard Esports said. “We’re incredibly excited to be working with our friend and streetwear legend Jeff Staple on these team kits. Our players’ close partnership with Jeff can be seen and felt in the considered design elements included in the apparel. We cannot wait to see this gear worn on the streets of each of our Overwatch League team cities this season.”
“I have been observing esports for years and am a huge fan of what Overwatch League has been able to accomplish, so when they asked me to design their new kits, I was stoked,” Staple said. “It was a once-in-a-lifetime opportunity to bring the best of the esports and streetwear worlds together to create something totally unique & ground-breaking. The kits are not only specifically engineered to perform to players’ specifications, but they’re also designed to look great outside the arena.”
Staple has been in the industry for over two decades and has partnered with many top brands in the design, lifestyle, and entertainment space. Featuring his world-renowned Staple Pigeon, his unique style brings a new edge to each team brand.
Fans will be able to pre-order the new OWL X STAPLE jerseys beginning on Jan. 28 on shop.overwatchleague.com.
Image and Video Assets : LINK
About the Overwatch League™
The Overwatch League™ is the first major global professional esports league with city-based teams across Asia, Europe, and North America. Overwatch® was created by globally acclaimed publisher Blizzard Entertainment (a division of Activision Blizzard—Nasdaq: ATVI), whose iconic franchises have helped lay the foundations and push the boundaries of professional esports over the last 15 years. The latest addition to Blizzard's stable of twenty-two #1 games,[1] Overwatch was built from the ground up for online competition, with memorable characters and fast-paced action designed for the most engaging gameplay and spectator experiences. To learn more about the Overwatch League, visit www.overwatchleague.com.
[1] Sales and/or downloads, based on internal company records and reports from key distributors.
About Blizzard Entertainment, Inc.
Best known for blockbuster hits including World of Warcraft®, Hearthstone®, Overwatch®, the Warcraft®, StarCraft®, and Diablo® franchises, and the multi-franchise Heroes of the Storm®, Blizzard Entertainment, Inc. (https://www.blizzard.com), a division of Activision Blizzard (NASDAQ: ATVI), is a premier developer and publisher of entertainment software renowned for creating some of the industry's most critically acclaimed games. Blizzard Entertainment's track record includes twenty-two #1 games* and multiple Game of the Year awards. The company's online gaming service, Blizzard Battle.net®, is one of the largest online-gaming services in the world, with millions of active players.
*Sales and/or downloads, based on internal company records and reports from key distributors.
About Activision Blizzard Esports
Activision Blizzard Esports (ABE) is responsible for the development, operation, and commercialization of Activision Blizzard’s professional gaming properties including the Overwatch League™, the Call of Duty® League™, Call of Duty Challengers™, Hearthstone® Masters, StarCraft® II esports, Warcraft® III: Reforged™, and the World of Warcraft® Arena World Championship and Mythic Dungeon International, among others. ABE also operates Tespa, the leader in collegiate esports. It is ABE’s vision to be the most innovative, scalable, and valuable developer of global competitive entertainment.
OVERWATCH, OVERWATCH LEAGUE and the OVERWATCH LEAGUE logo are trademarks or registered trademarks of Blizzard Entertainment, Inc., in the U.S. and/or other countries. All other names are trademarks of their respective holders.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves the Overwatch League’s expectations, plans, intentions or strategies regarding the future, including statements about the collaboration with Jeff Staple and the dates of the Overwatch League 2020 season, are forward-looking statements that are not facts and involve a number of risks and uncertainties. Factors that could cause the Overwatch League’s actual future results to differ materially from those expressed in the forward-looking statements set forth in this release include unanticipated product delays and other factors identified in the risk factors sections of Activision Blizzard’s most recent annual report on Form 10-K and any subsequent quarterly reports on Form 10-Q. The forward-looking statements in this release are based upon information available to the Overwatch League and Activision Blizzard as of the date of this release, and neither the Overwatch League nor Activision Blizzard assumes any obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of the Overwatch League or Activision Blizzard and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200116005551/en/
Contact information
Mark Van Lommel
Overwatch League
949-955-1380 x61147
MVanLommel@overwatchleague.com
Kevin Scarpati
Overwatch League
949-955-1380 x61298
Kscarpati@overwatchleague.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA ® Commercialization in Central and Eastern Europe7.1.2026 09:30:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom